A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4+ and CD8+ T cell responses, as well as long-lived plasma and memory B cell responses. Additionally, we detect robust and sustained neutralizing antibody responses and the antibodies elicited by nucleoside-modified mRNA vaccines do not show antibody-dependent enhancement of infection in vitro. Our findings suggest that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.
Laczkó, D; Hogan, MJ; Toulmin, SA; Hicks, P; Lederer, K; Gaudette, BT; Castaño, D; Amanat, F; Muramatsu, H; Oguin, TH; Ojha, A; Zhang, L; Mu, Z; Parks, R; Manzoni, TB; Roper, B; Strohmeier, S; Tombácz, I; Arwood, L; Nachbagauer, R; Karikó, K; Greenhouse, J; Pessaint, L; Porto, M; Putman-Taylor, T; Strasbaugh, A; Campbell, T-A; Lin, PJC; Tam, YK; Sempowski, GD; Farzan, M; Choe, H; Saunders, KO; Haynes, BF; Andersen, H; Eisenlohr, LC; Weissman, D; Krammer, F; Bates, P; Allman, D; Locci, M; Pardi, N
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)